Safety/toxicological profile of THC
| Acute oral toxicity LD50 | >500 mg/kg body weight |
| Acute dermal toxicity LD50 | >2000 mg/kg body weight |
| Primary skin irritation test | Did not cause any irritation |
| Mucous membrane irritation test | Did not cause any irritation |
| AMES test | Non-mutagenic |
Safety studies on Tetrahydrocurcuminoids (THC)
Sabinsa conducted a single centered, open labeled clinical trial in humans for establishing safety of oral supplementation of THCs. The study enrolled 20 healthy human volunteers and orally administered 300 mg of THC once daily for 28 days. Laboratory parameters analyzed at the baseline and at end of the study showed no significant difference in hematological parameters such as leukocyte count, erythrocyte count, hemoglobin, hematocrit, platelets etc. There was no significant change in body mass index (BMI) and adverse effects observed during the study.
The study concludes that THCs supplemented orally at a dose of 300 mg once daily for 28 days is safe.